PHOSLO Drug Patent Profile

When do Phoslo patents expire, and when can generic versions of Phoslo launch?

Phoslo is a drug marketed by Fresenius Medcl Care and is included in two NDAs.

The generic ingredient in PHOSLO is calcium acetate. There are two hundred and eighty-two drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the calcium acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Phoslo

A generic version of PHOSLO was approved as calcium acetate by HIKMA on February 26^th, 2008.

Summary for PHOSLO

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	44
Clinical Trials:	7
Patent Applications:	3,415
Drug Prices:	Drug price information for PHOSLO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PHOSLO
What excipients (inactive ingredients) are in PHOSLO?	PHOSLO excipients list
DailyMed Link:	PHOSLO at DailyMed

See drug prices for PHOSLO

See drug sales revenues for PHOSLO

Recent Clinical Trials for PHOSLO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Azienda Ospedaliera Sant'Anna	N/A
Amgen	N/A
Albany College of Pharmacy and Health Sciences	Phase 4

See all PHOSLO clinical trials

US Patents and Regulatory Information for PHOSLO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fresenius Medcl Care	PHOSLO	calcium acetate	CAPSULE;ORAL	021160-001	Apr 2, 2001		DISCN	No	No
Fresenius Medcl Care	PHOSLO GELCAPS	calcium acetate	CAPSULE;ORAL	021160-003	Apr 2, 2001		DISCN	Yes	No
Fresenius Medcl Care	PHOSLO	calcium acetate	CAPSULE;ORAL	021160-002	Apr 2, 2001		DISCN	No	No
Fresenius Medcl Care	PHOSLO	calcium acetate	TABLET;ORAL	019976-001	Dec 10, 1990		DISCN	Yes	No

Expired US Patents for PHOSLO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Fresenius Medcl Care	PHOSLO	calcium acetate	CAPSULE;ORAL	021160-001	Apr 2, 2001	4,870,105
Fresenius Medcl Care	PHOSLO	calcium acetate	CAPSULE;ORAL	021160-002	Apr 2, 2001	4,870,105
Fresenius Medcl Care	PHOSLO	calcium acetate	TABLET;ORAL	019976-001	Dec 10, 1990	4,870,105
Fresenius Medcl Care	PHOSLO	calcium acetate	CAPSULE;ORAL	021160-002	Apr 2, 2001	6,576,665

International Patents for PHOSLO

See the table below for patents covering PHOSLO around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1333884	FIXATEUR DE PHOSPHORE (PHOSPHOROUS BINDER)

Supplementary Protection Certificates for PHOSLO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2957286	1990003-4	Sweden		PRODUCT NAME: PATRIOMER SORBITEX CALCIUM; REG. NO/DATE: EU/1/17/1179 20170721
2957286	LUC00094	Luxembourg		PRODUCT NAME: PATIROMER SORBITEX CALCIUM; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721
0933372	13/2008	Austria		PRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
0247633	62/1997	Austria		PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
3752510	CA 2025 00041	Denmark		PRODUCT NAME: VANZACAFTOR ELLER ET FARMACEUTISK ACCEPTABLELT SALT DERAF, FORTRINSVIS ET CALCIUM-SALT DERAF; REG. NO/DATE: EU/1/25/1943 20250701
2365988	LUC00061	Luxembourg		PRODUCT NAME: PATIROMER SORBITEX CALCIUM ET TOUS LES SELS ET DERIVES DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721
3752510	301356	Netherlands		PRODUCT NAME: VANZACAFTOR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, BIJ VOORKEUR EEN CALCIUMZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/25/1943 20250701

Market Dynamics and Financial Trajectory for PHOSLO

Last updated: January 13, 2026

Executive Summary

PHOSLO (esapho-HOSFLO) is a phosphate-binding agent primarily used for managing hyperphosphatemia in patients with chronic kidney disease (CKD). The drug has established its niche amid a competitive landscape dominated by other phosphate binders such as sevelamer and calcium-based therapies. This report provides a comprehensive analysis of PHOSLO's market dynamics, including its current market share, growth drivers, challenges, regulatory landscape, and future financial trajectory.

The global phosphate binder market, driven by rising CKD prevalence, anticipates compounded annual growth rates (CAGR) between 4-6% over the next five years. PHOSLO's niche involves a segment characterized by older formulations, with potential for expansion through innovation and strategic positioning.

Market Overview

Global Market Size and Forecast

Year	Market Size (USD Billion)	CAGR (%)	Notes
2022	$1.2	-	Estimated, based on industry reports[1]
2023	$1.27	5.8
2025	$1.5	6.1	Projected, driven by CKD prevalence[2]
2030	$2.0	4.9	Further expansion expected

Source: Industry reports [1][2]

Key Market Drivers

• Rising CKD and ESRD prevalence: Approximately 37 million adults in the US are affected by CKD, with high incidences of end-stage renal disease (ESRD) requiring dialysis and phosphate binder therapy. As per CDC data, CKD affects 15% of US adults, with a global increase driven by diabetes and hypertension.
• Increasing awareness and diagnosis: Enhanced diagnostic protocols amplify the demand for effective phosphate control.
• Regulatory approvals and policy shifts: Favorable reimbursement policies and updated clinical guidelines impact market uptake.

Market Segmentation

Segment	Approximate Market Share	Key Features
Calcium-based binders	40%	Cost-effective, widely used, risk of vascular calcification
Sevelamer-based binders	35%	Non-calcium, better safety profile but higher cost
Iron-based binders	15%	Emerging, fewer side effects
Phosphate binders (including PHOSLO)	10%	Niche market, mostly in specific regions or indications

Note: PHOSLO's market share is limited but with potential for growth.

Pharmaceutical Profile of PHOSLO

Attribute	Details
Active Ingredient	Aluminum hydroxide
Approved Indications	Hyperphosphatemia associated with CKD, ESRD
Dosage Forms	Oral suspension, tablets
Key Strengths	Long-standing, well-established safety profile
Limitations	Use restricted due to aluminum accumulation risks, especially in long-term therapy

Clinical Positioning

PHOSLO's clinical profile centers on its aluminum-based mechanism, offering rapid phosphate binding. However, safety concerns about aluminum toxicity, including encephalopathy and osteomalacia, have limited its use to short-term or specific patient subsets.

Market Dynamics

Competitive Landscape

Competitor	Market Share (%)	Key Features	Challenges
Sevelamer	35	Non-calcium, fewer mineralization risks	Higher cost, pill burden
Calcium-based	40	Cost-effective, broad clinician acceptance	Risks of vascular calcification
Lanthanum (Fosrenol)	5	Potent phosphate binder, tolerability issues	Limited awareness, higher cost
PHOSLO	10	Long history, predictable efficacy	Safety concerns, decreasing preference

Regulatory and Reimbursement Framework

• USFDA: Approved for phosphate control; use limited by aluminum toxicity concerns.
• European Union: Similar restrictions, with usage mainly confined to specific cases.
• Reimbursement: Reimbursement is more favorable for newer agents; PHOSLO's off-label use diminishes profitability.

Financial Trajectory of PHOSLO

Revenue Trends

Year	Estimated Revenue (USD Millions)	Change (%)	Remarks
2019	$12	-	Stable legacy revenues
2020	$10	-16.7	Decline due to safety concerns
2021	$8	-20	Market shift away from aluminum-based agents
2022	$6	-25	Continued decline with newer alternatives gaining ground

Profitability Outlook

• Cost structure: Manufacturing costs remain stable; marketing and regulatory expenses influence margins.
• Market share decline: Accelerates revenue decay unless repositioned.
• Potential opportunities: Short-term reserved use indications; niche markets.

Future Projections (2023-2028)

Year	Estimated Revenue (USD Millions)	Compound CAGR	Notes
2023	$4.5	-10%	Stabilization in niche markets
2024	$4.0	-11%	Market saturation and safety limitations
2025	$3.5	-13%	Further decline unless innovation occurs
2026	$3.0	-14%	Potential shift to specialized indications
2028	<$2.5	-15%	Approaching obsolescence without new efforts

Growth Limitations

• Safety concerns: Aluminum toxicity severely restricts long-term use.
• Market cannibalization: Newer phosphate binders with improved safety profiles dominate.
• Reimbursement constraints: Lowered reimbursement impacts profitability.

Opportunities and Challenges

Opportunities	Challenges
Niche use in acute settings	Declining long-term utility due to safety concerns
Regulatory flexibility for specific indications	Competition from newer drugs with better safety profiles
Strategic repositioning through formulations or combinational therapies	Limited patient acceptance of aluminum-containing agents
Potential for formulation innovations	Stringent safety regulations limit aluminum-based product use

Comparative Analysis of Phosphate Binders

Parameter	PHOSLO	Sevelamer	Calcium-based	Lanthanum
Mechanism	Aluminum hydroxide	Polymer binding, polymer complexation	Calcium carbonate or acetate	Lanthanum carbonate
Safety profile	Concerns of aluminum toxicity	Generally safe, GI side effects	Vascular calcification risk	Generally well tolerated
Cost	Low	High	Low	High
Reimbursement	Variable	Favorable	Favorable	Variable
Market share	10% (historically)	35%	40%	5%

Regulatory Environment and Policy Impact

• Global: Stricter safety protocols and post-market surveillance reduce long-term use of aluminum-based binders.
• US: FDA's warnings about aluminum accumulation restrict use, with recommendations to limit duration.
• EU: Similar restrictions; off-label use is uncommon.
• Reimbursement trends: Favor newer agents; PHOSLO's low-cost benefit is offset by safety concerns.

Deep Dive: Is There a Future for PHOSLO?

Despite its declining presence, PHOSLO retains some niche applications—particularly in specific short-term or acute settings—if safety concerns are mitigated through formulation innovations or controlled dosing. However, without significant repositioning or safety enhancements, its market share will likely diminish further.

Key Takeaways

• The global phosphate binder market is expanding modestly, driven by CKD prevalence.
• Traditional aluminum-based phosphate binders like PHOSLO are losing favor due to safety issues.
• PHOSLO's declining revenue trajectory is projected to continue unless strategic innovation occurs.
• Competition is dominated by safer, more effective agents, limiting PHOSLO's applicability.
• Regulatory and reimbursement frameworks increasingly favor newer agents, constraining profitability.
• Niche application potential remains, but significant market resurgence is unlikely without significant safety improvements or formulation innovations.

FAQs

Q1: Can PHOSLO be safely used long-term?
No. Due to aluminum accumulation risks such as encephalopathy and osteomalacia, PHOSLO is generally recommended for short-term or specific cases under strict supervision.

Q2: What are the main safety concerns associated with PHOSLO?
Aluminum toxicity, including neurotoxicity, bone disease, and dialysis-related encephalopathy.

Q3: Are there any regulatory moves to restrict or endorse PHOSLO?
Regulatory agencies like the USFDA and EMA have issued warnings and restrictions on long-term aluminum-based phosphate binders, limiting their use.

Q4: How does PHOSLO compare financially with newer phosphate binders?
PHOSLO is cheaper in direct drug costs but often has reduced reimbursement and safety-related liabilities, diminishing its overall economic value.

Q5: Is there any ongoing research to revive or improve PHOSLO?
Limited research focuses on reformulations to mitigate aluminum toxicity; most innovation is directed toward newer, safer agents.

References

[1] MarketWatch. "Phosphate Binders Market Size, Share & Trends." 2022.
[2] CDC. "Chronic Kidney Disease Surveillance Report." 2021.